论文部分内容阅读
目的探讨酪氨酸激酶c-Src及Erb B2的表达与上皮性卵巢癌的关系,为卵巢癌生物靶向治疗的研发提供新的靶点。方法采用免疫组织化学法分别检测c-Src及Erb B2在上皮性卵巢癌(n=82)、卵巢良性肿瘤(n=25)和正常卵巢组织(n=20)的表达情况,并分析这两项指标的表达与卵巢癌临床病理特征及预后的关系。结果在卵巢癌患者中,c-Src、Erb B2的阳性表达率均显著高于卵巢良性病变和正常卵巢组织(P<0.05)。c-Src的表达强度与患者年龄呈正相关,年龄>40岁c-Src强阳性率显著高于≤40岁(P<0.05)。Erb B2的表达水平与患者的临床分期呈正相关,Ⅲ、Ⅳ期的Erb B2阳性率显著高于Ⅰ、Ⅱ期(P<0.05)。Erb B2阴性的患者5年累计生存率显著高于其表达阳性的患者(P<0.05)。多因素生存分析显示Erb B2是影响卵巢癌预后的独立因素之一。结论c-Src、Erb B2可能与卵巢癌的发生有关。Erb B2可作为预测卵巢癌患者生存的指标之一。
Objective To investigate the relationship between the expression of tyrosine kinases c-Src and Erb B2 and epithelial ovarian cancer, and to provide a new target for the research and development of biological targeted therapy of ovarian cancer. Methods The expressions of c-Src and Erb B2 were detected by immunohistochemistry in epithelial ovarian cancer (n = 82), benign ovarian tumor (n = 25) and normal ovarian tissue (n = 20) Relationship between the expression of hs - CRP and the clinicopathological features and prognosis of ovarian cancer. Results The positive rates of c-Src and Erb B2 in ovarian cancer patients were significantly higher than those in benign ovarian lesions and normal ovarian tissues (P <0.05). The expression of c-Src was positively correlated with the age of patients. The strong positive rate of c-Src> 40 years old was significantly higher than that of ≤40 years old (P <0.05). The expression level of Erb B2 was positively correlated with the clinical stage of patients. The positive rate of Erb B2 in stage Ⅲ and Ⅳ was significantly higher than that in stage Ⅰ and Ⅱ (P <0.05). The 5-year cumulative survival rate was significantly higher in Erb B2-negative patients than in those with positive expression (P <0.05). Multivariate survival analysis showed that Erb B2 was an independent factor affecting the prognosis of ovarian cancer. Conclusion c-Src, Erb B2 may be related to the occurrence of ovarian cancer. Erb B2 can be used as an indicator of survival in patients with ovarian cancer.